oxybutynin transdermal system

This page contains recent news articles, when available, and an overview of oxybutynin transdermal system but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

UPDATE 1-Watson, Barr settle patent dispute over Oxytrol  -  ‎Oct 28, 2009‎
N)said it has reached an agreement to settle a patent dispute with Barr Pharmaceuticals over Watson's Oxytrol, or Oxybutynin Transdermal System product. ... Reuters

Watson Pharmaceuticals signs license agreement with Barr Laboratories for ...  -  ‎Oct 29, 2009‎
Inc., a specialty pharmaceutical company, on outstanding patent litigation related to Watson's Oxytrol(R) (Oxybutynin Transdermal System, 3.9mg/24hr. ... Trading Markets (press release)

Markets in Brief  -  ‎Oct 29, 2009‎
...said it has reached an agreement to settle a patent dispute with Barr Pharmaceuticals over Watson's Oxytrol, or Oxybutynin Transdermal System, product. ... Ha'aretz

Barr Confirms Patent Challenge of Oxytrol(R)  -  Oct 24, 2008
Oxytrol (oxybutynin transdermal system) had annual sales of approximately $39 million in the US, based on IMS sales data ending August 2008. ... International Business Times

Watson Announces Positive Data for Its New Investigational Products...  -  May 21, 2008
The abstract (Steady-State Pharmacokinetics of an Investigational Oxybutynin Topical Gel in Comparison with Oxybutynin Transdermal System) was presented by ... RedOrbit

Sarkozy, Lehman, Kaupthing, Belvedere in Court News  -  Oct 27, 2008
Administration to make its own extended-release oxybutynin transdermal system violates patents awarded since 1997 related to Watson's Oxytrol patch. ... Bloomberg

Urinary Incontinence: Choices in Medical Therapy for Overactive...  -  Apr 1, 2007
OXYTROL Oxybutynin Transdermal System [package insert]. Corona, Calif: Watson Pharma, Inc; 2001. 21. Davila GW. Transdermal oxybutynin: a new treatment for ... $4.95 - Consultant - ECNext

Press Release: Watson Announces Positive Data for Its New …  -  May 21, 2008
The abstract (Steady-State Pharmacokinetics of an Investigational Oxybutynin Topical Gel in Comparison with Oxybutynin Transdermal System) was presented by ... Pay-Per-View - PR Newswire - HighBeam Research

ICS 2007 ABST[89] - Transdermal Oxybutynin for Overactive Bladder: …  -  Aug 23, 2007
...the safety and effectiveness of the oxybutynin transdermal system (OXY-TDS) in a community-based population of adults with overactive bladder (OAB) [1]. ... UroToday International Journal

Article: Watson is suing Barr for patent infringement - Deseret News...  -  Oct 25, 2008
Administration to make its own extended-release oxybutynin transdermal system violates patents awarded since 1997 related to Watson's Oxytrol patch. ... Pay-Per-View - Deseret News - HighBeam Research

Newer agents for the management of overactive bladder.(Clinical...  -  Dec 15, 2006
Oxytrol (oxybutynin transdermal system) [Package insert]. Corona, Calif.: Watson Pharma, 2003. 5. Vesicare (solifenacin succinate) [Package insert]. ... $4.95 - American Family Physician - ECNext

Paladin Labs buys into film technology with BioEnvelop deal  -  Apr 26, 2007
...treatment of severe allergic reactions; and Oxytrol (oxybutynin transdermal system), a clear patch formulation of a treatment for overactive bladder. In-PharmaTechnologist.com

Article: FDA approves Taclonex[R] for treatment of psoriasis.(New …  -  Jun 1, 2006
Inc.'s (WPI) Oxytrol (oxybutynin transdermal system), the first and only transdermal therapy to treat overactive bladder (OAB), with symptoms of urinary ... Pay-Per-View - Dermatology Nursing - HighBeam Research

Paladin Reports 2005 First Quarter Financial Results.  -  May 5, 2005
...provides drug insurance coverage for an estimated 3.2 million residents of Quebec, gave its approval to list Oxytrol(R) (oxybutynin transdermal system). ... $4.95 - Business Wire - ECNext

Press Release: XL TechGroup and Procter & Gamble Form Strategic …  -  Jul 18, 2005
Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced that OXYTROL(TM) (oxybutynin transdermal system), the first and ... Pay-Per-View - PR Newswire - HighBeam Research

Watson Notified of OXYTROL(R) Patent Challenge  -  Oct 1, 2008
...and DrugAdministration (FDA) by a generic filer requesting approval to market and sella generic version of OYXTROL(R) (Oxybutynin Transdermal System). ... International Business Times

Press Release: Barr Confirms Patent Challenge of Oxytrol(R). - PR …  -  Oct 24, 2008
Inc., has initiated a challenge of the patents listed by Watson Laboratories, Inc. in connection with its Oxytrol(R) (oxybutynin transdermal system). ... Pay-Per-View - PR Newswire - HighBeam Research

Press Release: Watson Notified of OXYTROL(R) Patent Challenge. - PR …  -  Oct 1, 2008
...and Drug Administration (FDA) by a generic filer requesting approval to market and sell a generic version of OYXTROL(R) (Oxybutynin Transdermal System). ... Pay-Per-View - PR Newswire - HighBeam Research

Kentera - OAB patientengerecht therapiert  -  Jul 6, 2007
Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community based, randomized study, 2006, ... Ärztliche Praxis Gesundheitszeitung

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.